The relation between persistence, as measured by resistance to change, and resurgence has been examined with nonhuman animals but not systematically with humans. The present study examined persistence and resurgence with undergraduate students engaging in a computer task for points exchangeable for money. In Phase 1, a target response was maintained on a multiple variable-interval (VI) 15-s (Rich) VI 60-s (Lean) schedule of reinforcement. In Phase 2, the target response was extinguished while an alternative response was reinforced at equal rates in both schedule components. In Phase 3, the target and the alternative responses were extinguished. In an additional test of persistence (Phase 4), target responding was reestablished as in Phase 1 and then disrupted by access to videos in both schedule components. In Phases 2 and 4, target responding was more persistent in the Rich than in the Lean component. Also, resurgence generally was greater in the Rich than in the Lean component in Phase 3. The present findings with humans extend the generality of those obtained with nonhuman animals showing that higher reinforcement rates produce both greater persistence and resurgence, and suggest that common processes underlie response persistence and relapse.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.beproc.2016.01.010 | DOI Listing |
Rheumatol Ther
January 2025
Biosplice Therapeutics, Inc., 9360 Towne Centre Dr, San Diego, CA, 92121, USA.
Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.
Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.
BMJ Open
January 2025
Department of Emergency Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
Introduction: Traumatic injuries are a significant public health concern globally, resulting in substantial mortality, hospitalisation and healthcare burden. Despite the establishment of specialised trauma centres, there remains considerable variability in trauma-care practices and outcomes, particularly in the initial phase of trauma resuscitation in the trauma bay. This stage is prone to preventable errors leading to adverse events (AEs) that can impact patient outcomes.
View Article and Find Full Text PDFCancer Lett
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan 430022, China. Electronic address:
This study, conducted as part of a multicenter phase III clinical trial, aimed to assess the utility of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) in comparing the efficacy of short-course and long-course chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). A total of 244 plasma samples from 79 LARC patients undergoing neoadjuvant therapy (NAT) before surgery were collected at various time points. Targeted deep sequencing using a novel MRD panel was performed.
View Article and Find Full Text PDFNeurosci Biobehav Rev
January 2025
Laboratory of Molecular and Systems Neurobiology, Department of Physiology and Neurobiology, Eötvös Loránd University.
The role of prolactin in sleep regulation has been the subject of extensive research over the past 50 years, resulting in the identification of multiple, disparate functions for the hormone. Prolactin demonstrated a characteristic circadian release pattern with elevation during dark and diminution during light. High prolactin levels were linked to non-rapid eye movement sleep and electroencephalogram delta activity in humans.
View Article and Find Full Text PDFGene
January 2025
Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
The oncoprotein c-Myc is expressed in all breast cancer subtypes, but its expression is higher in triple-negative breast cancer (TNBC) compared to estrogen receptor (ER+), progesterone receptor (PR+), or human epidermal growth factor receptor 2 (HER2+) positive tumors. The c-Myc gene is crucial for tumor progression and therapy resistance, impacting cell proliferation, differentiation, senescence, angiogenesis, immune evasion, metabolism, invasion, autophagy, apoptosis, chromosomal instability, and protein biosynthesis. Targeting c-Myc has emerged as a potential therapeutic strategy for TNBC, a highly aggressive and deadly breast cancer form.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!